India’s healthcare ecosystem is evolving rapidly, and Redcliffe Labs is emerging as a major force in making diagnostics affordable and accessible at people’s doorsteps.
Founded by Aditya Kandoi and Dheeraj Jain, the company has built a strong network of over 80 labs and runs India’s largest home sample collection service. Whether you’re in a metro city or a small town, Redcliffe makes it easy to get diagnostic tests done from the comfort of your home.
In FY25, Redcliffe Labs reported revenues of ₹419 crore, reflecting a robust 20% year-on-year growth, while also reducing its operating losses from -38% to -21%. Diagnostic services remain its core strength, contributing 95% of total revenue. The company detected over 2.5 million cases during the year — with more than 70% coming from Tier II and Tier III towns — marking a significant step towards accessible healthcare for all.
With a healthy gross margin of 70%, Redcliffe aims to expand this to 74% by next year and achieve ₹560 crore in revenue by FY26. Growth is being driven through new lab openings and strategic acquisitions, including the recent $7 million acquisition of Celara Diagnostics.
Supported by $113 million in funding, Redcliffe has the financial muscle to fuel this expansion.
Despite competition from established players like Thyrocare and Tata 1mg, Redcliffe stands out by targeting underpenetrated geographies. By FY28, it aims to operate in 300 cities with 150 labs. Redcliff Labs is on a path to make high-quality diagnostics affordable for millions of Indians.
